论文部分内容阅读
目的评价FOLFOX4方案治疗晚期大肠癌的疗效与安全性。方法按FOLFOX4方案给药,奥沙利铂85mg/m2,静脉滴注2h,第1d;CF200mg/m2,静脉滴注2h,第1,2d;5-FU400mg/m2,于CF滴完后静脉注射10min,第1,2d;5-FU600mg/m2,持续泵入22h,第1,2d;每2~3周重复。结果入组观察48例,可评价疗效者48例,其中CR5例(10.4%),PR14例(29.2%),CR+PR共19例,近期客观有效率39.6%;SD 20例(41.7%),PD 9例(18.8%)。中位TTP 9.3个月,中位OS 22.4个月。不良反应主要为白细胞减少,消化道不良反应较轻,较明显的毒副反应为周围神经毒性,无化疗相关死亡。结论FOLFOX4方案治疗晚期大肠癌癌疗效较高,不良反应轻而且安全。
Objective To evaluate the efficacy and safety of FOLFOX4 regimen in the treatment of advanced colorectal cancer. Methods FOLFOX4 regimen was given. Oxaliplatin 85mg / m2, intravenous drip 2h, 1d; CF200mg / m2, intravenous drip 2h, 1st and 2nd, 5-FU400mg / m2, 10min, first and second days; 5-FU600mg / m2, continuous pumping 22h, 1st and 2nd day; repeated every 2 to 3 weeks. Results There were 48 cases in which 48 cases could be evaluated. Among them, CR5 cases (10.4%), PR14 cases (29.2%), CR + PR cases (19 cases) , PD 9 cases (18.8%). Median TTP 9.3 months, median OS 22.4 months. Adverse reactions mainly leukopenia, gastrointestinal adverse reactions, the more obvious side effects of peripheral neurotoxicity, no chemotherapy-related deaths. Conclusion FOLFOX4 regimen is effective in treating advanced colorectal cancer with light and safe adverse reactions.